Chemoradiation followed by immunotherapy for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a treatment for locally advanced esophageal cancer. You'll receive chemoradiation (chemo plus radiation) followed by a maintenance drug (a PD-1 inhibitor) to help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of esophageal cancer called squamous cell carcinoma.
- Your cancer is stage 3 or 4 without spread to distant organs, or spread only to lymph nodes in the neck area.
- You are 18 years or older and in generally good health (able to do daily activities).
- You have not had immunotherapy (like PD-1 inhibitors) before.
- You do not have an active autoimmune disease, uncontrolled heart problems, or active infections like hepatitis B/C or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach for advanced esophageal cancer that combines targeted radiation, immunotherapy, and chemotherapy. It aims to see if skipping radiation to certain lymph nodes can improve outcomes while reducing side effects.
This trial tests a new combination of proton beam radiation, chemotherapy, and immunotherapy for locally advanced esophageal squamous cell carcinoma. It aims to see if this approach is safe and may help people whose cancer cannot be surgically removed.
This study tests a combination of chemotherapy and immunotherapy before and after standard chemoradiation for people with locally advanced esophageal squamous cell carcinoma. It aims to see if this approach can improve outcomes with manageable side effects.
This trial tests a combination of low-dose radiation and immunotherapy for people with advanced esophageal cancer that cannot be surgically removed. The goal is to see if this approach is safe and effective after initial treatment.
This trial tests whether adding immunotherapy to standard chemoradiation can help people with unresectable locally advanced esophageal cancer. It aims to improve outcomes for those who cannot have surgery.
This trial studies whether adding an anti-PD-1 immunotherapy (with chemotherapy) together with radiation can help people with advanced esophageal squamous cell cancer. It’s for cases where surgery or standard definitive chemoradiation can’t be done, or the cancer has spread to distant sites.
Hear when a new Esophageal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.